Cancel anytime
BioLineRx Ltd (BLRX)BLRX
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: BLRX (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: 19.27% | Upturn Advisory Performance 2 | Avg. Invested days: 25 |
Profits based on simulation | Stock Returns Performance 2 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: 19.27% | Avg. Invested days: 25 |
Upturn Star Rating | Stock Returns Performance 2 |
Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.88M USD |
Price to earnings Ratio - | 1Y Target Price 9.83 |
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Volume (30-day avg) 398915 | Beta 0.87 |
52 Weeks Range 0.39 - 1.89 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 42.88M USD | Price to earnings Ratio - | 1Y Target Price 9.83 |
Dividends yield (FY) - | Basic EPS (TTM) -0.45 | Volume (30-day avg) 398915 | Beta 0.87 |
52 Weeks Range 0.39 - 1.89 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-11-04 | When BeforeMarket |
Estimate -0.1 | Actual - |
Report Date 2024-11-04 | When BeforeMarket | Estimate -0.1 | Actual - |
Profitability
Profit Margin -176.67% | Operating Margin (TTM) -107.05% |
Management Effectiveness
Return on Assets (TTM) -35.23% | Return on Equity (TTM) -171.94% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 29838070 | Price to Sales(TTM) 2.52 |
Enterprise Value to Revenue 1.75 | Enterprise Value to EBITDA -0.67 |
Shares Outstanding 79943200 | Shares Floating 1092454166 |
Percent Insiders 8.54 | Percent Institutions 3.07 |
Trailing PE - | Forward PE - | Enterprise Value 29838070 | Price to Sales(TTM) 2.52 |
Enterprise Value to Revenue 1.75 | Enterprise Value to EBITDA -0.67 | Shares Outstanding 79943200 | Shares Floating 1092454166 |
Percent Insiders 8.54 | Percent Institutions 3.07 |
Analyst Ratings
Rating 4.5 | Target Price 14 | Buy 1 |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 4.5 | Target Price 14 | Buy 1 | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
BioLineRx Ltd. - A Comprehensive Overview
Company Profile:
History and Background: BioLineRx Ltd. (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel oncology drugs. Founded in 2003, the company is headquartered in Ness Ziona, Israel, with additional offices in the United States. BioLineRx focuses on treatments for cancer and blood disorders through the development of small molecule drug candidates, including BL-8040.
Core Business Areas:
- Oncology: This segment includes the development of BL-8040, a novel oncology candidate for the treatment of solid tumors and hematological malignancies.
- Blood Disorders: BioLineRx is developing BL-7055, a novel oral mucoadhesive for the treatment of oral mucositis.
Leadership Team: The company's leadership team comprises industry veterans with experience in drug development, commercialization, and finance. The CEO of BioLineRx is Dr. Ralph Yassur, and the Chief Medical Officer is Dr. Martin S. Tallman.
Top Products and Market Share:
Products:
- BL-8040: In Phase I/II clinical trials, targeting solid tumors and hematological malignancies.
- BL-7055: In development stage, intended for treatment of oral mucositis.
Market Share: Both BL-8040 and BL-7055 are in the development stage and do not currently have any market share.
Comparison to Competitors: Direct competitors for BL-8040 are small and mid-cap biotech companies with similar oncology-focused products in clinical development. However, BL-8040's mode of action and potential target range set it apart from competition. Competitors for BL-7055 include existing mucositis treatments like caphosol and other topical agents. BioLineRx aims to differentiate BL-7055 with its improved efficacy and ease of administration.
Total Addressable Market:
Oncology Market: Estimated at $155 billion in 2022 and projected to reach $232.3 billion by 2028 (CAGR 9.4%). Oral Mucositis Market: Estimated at $3 billion in 2022 and projected to reach $3.6 billion by 2028 (CAGR 4.2%).
Financial Performance:
Recent Results: BioLineRx reported a net loss of $37.5 million for the first quarter of 2023 compared to $34.5 million during the same period in 2022. Year-over-Year Comparison: Revenue and gross profit remained minimal in both quarters. The company continues to spend heavily on research and development activities. Cash Flow and Balance Sheet: Cash and cash equivalents were $23.9 million as of March 31, 2023. BioLineRx's cash burn rate requires additional funding for continued operations.
Dividends and Shareholder Returns: BioLineRx does not currently pay dividends and has historically focused on reinvesting earnings into research and development.
Growth Trajectory:
Historical Growth: Revenue remained limited over the past few years due to the development stage of the product portfolio. Future Projections: BioLineRx's growth prospects depend on the successful clinical development and potential regulatory approval of its product candidates, especially BL-8040. Recent Initiatives: The company is actively progressing in clinical trials for BL-8040 and exploring strategic acquisitions for expanding its oncology pipeline.
Market Dynamics: The oncology drug market is highly competitive and constantly evolving with new technologies. BioLineRx needs to remain innovative, develop strong partnerships, and navigate regulatory changes successfully for long-term growth.
Competitors: Major competitors for BL-8040 include: - Aclaris Therapeutics (ACRS) - Atara Biotherapeutics (ATRA) - ArQule (ARQL) - ImmunoGen (IMGN) - Syndax Pharmaceuticals (SNDX) Competitors for BL-7055 include: - Caphosol (Caphosol Inc.) - MuGard (Oragenics Inc.) - MouthKote (OraPharma Inc.)
BioLineRx's advantages: - Novel mode of action and broad-spectrum potential of BL-8040.
- Addressing high unmet need and offering improved patient experience with BL-7055. - Strong intellectual property portfolio. BioLineRx's disadvantages: - Early-stage product portfolio with inherent development and regulatory risks. - Limited financial resources require strategic capital management. - Intense competition within the market segments.
Potential Challenges and Opportunities:
Challenges: - Demonstration of clinical efficacy and safety in ongoing trials for BL-8040 and BL-7055. - Securing additional funding for continued R&D and potential commercialization efforts. - Navigating the competitive landscape and differentiating its products in the market. Opportunities: - Positive clinical outcomes of BL-8040 with potential market expansion and partnerships. - Successful launch of BL-7055 with high unmet clinical need and attractive market opportunity. - Strategic alliances and potential M&A to enhance pipeline and growth prospects.
Recent Acquisitions: BioLineRx has not acquired companies in the last 3 years. However, they actively seek partnerships and potential licenses for expanding their research and development activities.
AI-Based Fundamental Rating: While an AI-based fundamental rating cannot be provided for this report, BioLineRx holds promising potential in its oncology pipeline, but the uncertainty associated with clinical results and regulatory processes limits an immediate conclusive rating. Continuous evaluation based on upcoming trial data and company developments are crucial in the future.
Sources & Disclaimers: Information for this overview was derived from BioLineRx Ltd.’s official website, investor relations materials, recent news articles, and industry reports. The provided analysis should not be construed as financial advice, and individuals seeking investment decisions should conduct independent research and consult with qualified professionals.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLineRx Ltd
Exchange | NASDAQ | Headquaters | - |
IPO Launch date | 2011-07-25 | CEO | - |
Sector | Healthcare | Website | https://www.biolinerx.com |
Industry | Biotechnology | Full time employees | 79 |
Headquaters | - | ||
CEO | - | ||
Website | https://www.biolinerx.com | ||
Website | https://www.biolinerx.com | ||
Full time employees | 79 |
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.